⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22676996 | 0.78 | — | — | |
| SCHEMBL21727183 | 0.75 | CYP19A1 (0.33) | — | |
| SCHEMBL19575669 | 0.73 | ESR1 (0.32) | — | |
| SCHEMBL8372529 | 0.69 | NPC1 (0.37) | — | |
| SCHEMBL681335 | 0.68 | — | — | |
| SCHEMBL2756557 | 0.67 | BCHE (0.32) | — | |
| SCHEMBL15829387 | 0.65 | LOXL2 (0.33) | — | |
| SCHEMBL23347480 | 0.63 | TP53 (0.30) | — | |
| SCHEMBL1791983 | 0.62 | DAO (0.35) | — | |
| SCHEMBL21324884 | 0.62 | DAO (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |